OR-1855, an active metabolite of Levosimendan (HY-14286), has effect on myometrial contractility. OR-1855 exerts anti-inflammatory effects by inhibiting IL-1beta-induced ROS formation and NAD(P)H oxidase-dependent superoxide radical generation in HUVECs. OR-1855 inhibits IL-1beta-induced phosphorylation p38 MAPK, ERK1/2, c-Jun and JNK in HUVECs. OR-1855 can be used for the study of inflammation[1][2][3].
Molecular Weight:
203.25
Purity:
99.78
CAS Number:
[101328-85-2]
Formula:
C11H13N3O
Target:
Drug Metabolite,ERK,p38 MAPK,Reactive Oxygen Species (ROS)
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
